• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sheila A. Stamps Joins IQVIA Board of Directors

    1/26/22 5:01:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email

    IQVIA (NYSE:IQV) today announced the appointment of Sheila A. Stamps to its board of directors, effective today. Ms. Stamps brings more than four decades of strategic, governance and operational management experience. During her extensive career she held senior executive leadership positions in both public and private sector organizations, most recently as a senior investment advisor to the Comptroller of the State of New York for the NYS Common Retirement Fund and as Commissioner on the board of the New York State Insurance Fund, the state's largest provider of worker's compensation insurance. Prior to this, she was a Managing Director at Bank of America and Managing Director and Executive Management Committee Member at Bank One London (now, JPMorgan Chase).

    Ms. Stamps currently serves on the boards of three public companies, including Pitney Bowes, Inc, a leading provider of global shipping & mailing solutions, where she has been a member of the Audit and Compensation committees since 2020; Atlas Air Worldwide Holdings, Inc., a global provider of aircraft and aviation services, since 2018 where she serves as Chair of the Audit and Finance committee; and MFA Financial, Inc, a residential mortgage REIT, where she is a member of the Compensation and Nominating & Governance committees. She previously served on the board of CIT Group, Inc., a publicly traded financial holding company, as a member of the Audit and Nominating & Governance committees from 2014 until its recent merger with First Citizens BancShares, Inc in January 2022.

    "We are very pleased to welcome Sheila to our board of directors," said Ari Bousbib, chairman and CEO, IQVIA. "Her mix of global experience within the public & private sectors and extensive corporate governance experience from her service on public boards across a diverse set of industries will strengthen our board and provide unique benefit to IQVIA."

    Ms. Stamps has a BS in Management Sciences from Duke University and an MBA, Finance, from the University of Chicago. She also completed a Fellowship at Harvard University's Weatherhead Center for International Affairs. In 2021, she was recognized as a "Most Influential Black Corporate Director" by Savoy Magazine and among the "2019 Most Influential Corporate Directors" by WomenInc. Magazine.

    Following the appointment of Ms. Stamps, the IQVIA Board of Directors will be comprised of 11 directors, ten of whom are independent and four are women.

    About IQVIA

    IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 77,000 employees, IQVIA conducts operations in more than 100 countries.

    IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005944/en/

    Get the next $IQV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    11/3/2025$215.00Buy → Hold
    TD Cowen
    10/29/2025$258.00Neutral → Outperform
    Robert W. Baird
    10/9/2025$235.00Hold → Buy
    HSBC Securities
    9/9/2025$225.00Hold → Buy
    Jefferies
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    2/3/2025Buy → Neutral
    BTIG Research
    12/20/2024$250.00Overweight
    Stephens
    More analyst ratings

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    IQVIA downgraded by TD Cowen with a new price target

    TD Cowen downgraded IQVIA from Buy to Hold and set a new price target of $215.00

    11/3/25 9:08:28 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded IQVIA from Neutral to Outperform and set a new price target of $258.00

    10/29/25 7:49:07 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded IQVIA from Hold to Buy and set a new price target of $235.00

    10/9/25 8:19:14 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Wims Morris Leslie

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    11/7/25 5:02:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Goggins Colleen A

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    11/7/25 5:01:23 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Fasano Jim

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    11/7/25 5:00:45 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    SEC Filings

    View All

    SEC Form 8-K filed by IQVIA Holdings Inc.

    8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

    11/5/25 4:29:39 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by IQVIA Holdings Inc.

    144 - IQVIA HOLDINGS INC. (0001478242) (Subject)

    10/29/25 4:18:02 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by IQVIA Holdings Inc.

    10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)

    10/28/25 4:31:55 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEXT Oncology Expands to Japan in Joint Venture Partnership With Kansai Medical University

    With continued global expansion, NEXT Oncology is one of the world's largest Phase I Cancer Trial organizations. NEXT Oncology, an Avacare business, has expanded its services to Asia through a strategic partnership with Kansai Medical University in Osaka, Japan. Under the guidance of Dr. Toshio Shimizu as the Director of the Phase I program, Kansai Medical University will now offer patients in Japan the opportunity to participate in Phase I clinical trials as part of the global NEXT Oncology network. Dr. Shimizu is a Professor in the Department of New Experimental Therapeutics and Director of Early Phase I Drug Development Services at the Kansai Medical University Hospital, Osaka, Japan.

    11/5/25 9:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Reports Third-Quarter 2025 Results

    Revenue of $4,100 million, up 5.2 percent year-over-year GAAP Net Income of $331 million, Adjusted EBITDA of $949 million GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year Operating Cash Flow of $908 million; Free Cash Flow of $772 million, up 35 percent year-over-year, representing 150 percent of Adjusted Net Income IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to

    10/28/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the UBS Global Healthcare Conference on Tuesday, November 11, 2025 at 12:30 p.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the li

    10/21/25 4:15:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    2/7/25 7:03:59 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

    8/15/24 7:57:23 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

    2/14/24 4:11:54 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by IQVIA Holdings Inc. (Amendment)

    SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

    1/25/24 4:59:33 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Leadership Updates

    Live Leadership Updates

    View All

    IQVIA Appoints Richard Staub III President of Research & Development Solutions

    IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

    9/25/23 8:01:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

    IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

    6/7/22 8:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

    3/14/22 9:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Financials

    Live finance-specific insights

    View All

    IQVIA Reports Third-Quarter 2025 Results

    Revenue of $4,100 million, up 5.2 percent year-over-year GAAP Net Income of $331 million, Adjusted EBITDA of $949 million GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year Operating Cash Flow of $908 million; Free Cash Flow of $772 million, up 35 percent year-over-year, representing 150 percent of Adjusted Net Income IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to

    10/28/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2025 financial results before the market opens on Tuesday, October 28, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com.

    9/30/25 4:15:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Reports Second-Quarter 2025 Results

    Revenue of $4,017 million, up 5.3 percent year-over-year GAAP Net Income of $266 million, Adjusted EBITDA of $910 million GAAP Diluted Earnings per Share of $1.54, Adjusted Diluted Earnings per Share of $2.81 R&D Solutions quarterly bookings of $2.5 billion, representing a book-to-bill ratio of 1.12x R&D Solutions contracted backlog of $32.1 billion, up 5.1 percent year-over-year TAS Revenue of $1,628 million, up 8.9 percent year-over-year Repurchased $607 million of common stock in the quarter, over $1 billion year-to-date IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence

    7/22/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care